Overview

HAT for the Treatment of Sepsis Associated With NASTI

Status:
Recruiting
Trial end date:
2022-10-10
Target enrollment:
Participant gender:
Summary
Evaluate the impact of HAT therapy versus placebo in the treatment of patients with an acute NSTI and sepsis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ascension Via Christi Hospitals Wichita, Inc.
Collaborator:
The University of Kansas School of Medicine - Wichita
Treatments:
Hydrocortisone
Vitamins